Roche's net rises strongly, buoyed by cancer drugs

Article Abstract:

Roche Holding AG doubles its first-half net profits thanks to strong sales of its cancer drugs and a hefty pre-tax gain that resulted from the company's having called in a bond issue. Established cancer medications, MabThera and Herceptin performed well, as did Avastin, the more recently introduced treatment for colorectal cancer.

Acquisitions & mergers, Sales, profits & dividends, Product information, Financial management, Drugs, Parent-to-subsidiary activities, Subsidiary-to-parent activities, Mergers, acquisitions and divestments, Finance, Company acquisition/merger, Biological products industry, Company sales and earnings, Company earnings/profit, Genentech Inc., Roche Holding Ltd., Company financing, Subsidiaries, divisions and units, DNA, Company product acquisition

---

Novartis buys American rights to antidepressant

Article Abstract:

Novartis AG of Switzerland has bought United States licensing rights to the antidepressant agomelatine from the pharmaceutical company Servier of France. Marketing approval for agomelatine was filed with the European Union regulator in 2005.

France, Alliances, partnerships, Licensing/Sales Agreements, Novartis AG, Licensing agreements, Company licensing agreement, NVTSY

---

Similar abstracts:

• Abstracts: Diageo earnings rise 21%, buoyed by North America. Goldman resigns as Diageo's corporate broker
• Abstracts: Lehman net is buoyed by bond operations. NYSE warns Specialist Firms about leaks
• Abstracts: G-7 cites new yan concern and weighs rules for funds. U.S. may boost holders' power to pick directors
• Abstracts: The German market for beer. The Italian market for beer. Beer in Italy
• Abstracts: European Airlines Face WMD-Insurance Problem. Ryanair faces a bumpy flight toward Aer Lingus

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.